Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Sep;72(3):634–636. doi: 10.1038/bjc.1995.385

High-dose interleukin 2 promotes bacterial translocation from the gut.

J V Reynolds 1, P Murchan 1, N Leonard 1, D B Gough 1, P Clarke 1, F B Keane 1, W A Tanner 1
PMCID: PMC2033909  PMID: 7669573

Abstract

Toxicity associated with high-dose recombinant interleukin 2 (rIL-2) therapy simulates a sepsis syndrome, but the mechanism remains unclear. We hypothesised that translocated gut-origin bacteria may be important. Fifty-one male rats were randomised to receive rIL-2 by intraperitoneal injection at doses (IU) of 10(5) (n = 15), 10(4) (n = 8), 10(3) (n = 8) or 10(2) (n = 8) twice daily, or a saline bolus (n = 12). After 5 days, ileal histomorphology was assessed and the mesenteric lymph node complex cultured. Results showed that colonisation of mesenteric lymph nodes with Escherichia coli occurred in all rats treated with 10(5) IU of rIL-2, and in 62%, 37% and 12% of rats treated with decreasing doses of rIL-2. No translocation was observed in control animals. An increase in submucosal lymphatics and occasional mucosal disruption was seen only in the group receiving 10(5) IU. These data show that rIL-2 promotes bacterial translocation and suggests a mechanism that may fuel high-dose rIL-2 toxicity in man.

Full text

PDF
634

Images in this article

635Figure 1
on p.635

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Crowley N. J., Seigler H. F. Possibilities of immunotherapy and gene therapy for malignant melanoma. Semin Surg Oncol. 1993 May-Jun;9(3):273–278. [PubMed] [Google Scholar]
  2. Deitch E. A. Multiple organ failure. Pathophysiology and potential future therapy. Ann Surg. 1992 Aug;216(2):117–134. doi: 10.1097/00000658-199208000-00002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Economou J. S., Hoban M., Lee J. D., Essner R., Swisher S., McBride W., Hoon D. B., Morton D. L. Production of tumor necrosis factor alpha and interferon gamma in interleukin-2-treated melanoma patients: correlation with clinical toxicity. Cancer Immunol Immunother. 1991;34(1):49–52. doi: 10.1007/BF01741324. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Goris R. J., te Boekhorst T. P., Nuytinck J. K., Gimbrère J. S. Multiple-organ failure. Generalized autodestructive inflammation? Arch Surg. 1985 Oct;120(10):1109–1115. doi: 10.1001/archsurg.1985.01390340007001. [DOI] [PubMed] [Google Scholar]
  5. Hack C. E., Wagstaff J., Strack van Schijndel R. J., Eerenberg A. J., Pinedo H. M., Thijs L. G., Nuijens J. H. Studies on the contact system of coagulation during therapy with high doses of recombinant IL-2: implications for septic shock. Thromb Haemost. 1991 May 6;65(5):497–503. [PubMed] [Google Scholar]
  6. Klausner J. M., Goldman G., Skornick Y., Valeri R., Inbar M., Shepro D., Hechtman H. B. Interleukin-2-induced lung permeability is mediated by leukotriene B4. Cancer. 1990 Dec 1;66(11):2357–2364. doi: 10.1002/1097-0142(19901201)66:11<2357::aid-cncr2820661118>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  7. Rahman R., Bernstein Z., Vaickus L., Penetrante R., Arbuck S., Kopec I., Vesper D., Douglass H. O., Jr, Foon K. A. Unusual gastrointestinal complications of interleukin-2 therapy. J Immunother (1991) 1991 Jun;10(3):221–225. doi: 10.1097/00002371-199106000-00009. [DOI] [PubMed] [Google Scholar]
  8. Rosenberg S. A. Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer. J Clin Oncol. 1992 Feb;10(2):180–199. doi: 10.1200/JCO.1992.10.2.180. [DOI] [PubMed] [Google Scholar]
  9. Rosenstein M., Ettinghausen S. E., Rosenberg S. A. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol. 1986 Sep 1;137(5):1735–1742. [PubMed] [Google Scholar]
  10. Siegel J. P., Puri R. K. Interleukin-2 toxicity. J Clin Oncol. 1991 Apr;9(4):694–704. doi: 10.1200/JCO.1991.9.4.694. [DOI] [PubMed] [Google Scholar]
  11. Snydman D. R., Sullivan B., Gill M., Gould J. A., Parkinson D. R., Atkins M. B. Nosocomial sepsis associated with interleukin-2. Ann Intern Med. 1990 Jan 15;112(2):102–107. doi: 10.7326/0003-4819-112-2-102. [DOI] [PubMed] [Google Scholar]
  12. Taniguchi T., Matsui H., Fujita T., Takaoka C., Kashima N., Yoshimoto R., Hamuro J. Structure and expression of a cloned cDNA for human interleukin-2. Nature. 1983 Mar 24;302(5906):305–310. doi: 10.1038/302305a0. [DOI] [PubMed] [Google Scholar]
  13. Van Leeuwen P. A., Boermeester M. A., Houdijk A. P., Ferwerda C. C., Cuesta M. A., Meyer S., Wesdorp R. I. Clinical significance of translocation. Gut. 1994 Jan;35(1 Suppl):S28–S34. doi: 10.1136/gut.35.1_suppl.s28. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Welbourn R., Goldman G., Kobzik L., Paterson I., Shepro D., Hechtman H. B. Interleukin-2 induces early multisystem organ edema mediated by neutrophils. Ann Surg. 1991 Aug;214(2):181–186. doi: 10.1097/00000658-199108000-00013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Wilmore D. W., Smith R. J., O'Dwyer S. T., Jacobs D. O., Ziegler T. R., Wang X. D. The gut: a central organ after surgical stress. Surgery. 1988 Nov;104(5):917–923. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES